Riyadh — Mubasher: Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) has signed distribution agreements on 29 July 2026 with subsidiaries of Cigalah Medical Company, according to a bourse filing.

The contracts appoint Cigalah Drug Store in the UAE and Cigalah Gulf Medical in Qatar as secondary distributors for the Saudi company's products in those markets.

The agreements carry an initial duration of five years and include an option for a two-year renewal.

According to the regulatory filing, there is no fixed value for the contracts, as the total financial outcome will depend on the volume of future operations and sales achieved within the targeted regional markets.

SPIMACO stated that these distribution arrangements do not result in an immediate financial impact.

The listed company further confirmed that there are no related parties involved in the transaction.

The move is part of the company's strategy to manage its pharmaceutical distribution network across the GCC region through established local partners.

In the second quarter (Q2) of 2026, the Saudi pharmaceutical entity SPIMACO posted net profits of roughly SAR 68.40 million amid ales hitting SAR 492.90 million.